High-activity tacrine-platinum (II) complexes and synthesis method and application thereof

A synthesis method and complex technology, applied in the field of medicine, can solve the problems such as the synthesis method and application of platinum (II) complexes that have not yet been seen, and achieve the effects of superior in vitro antitumor activity, significant inhibitory effect, and good medicinal value.

Active Publication Date: 2018-01-26
YULIN NORMAL UNIVERSITY
View PDF0 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

From structural analysis, its parent ring structure has better aromatic planarity, is a kind of excellent organic ligand; And also do not see the synthetic method and the platinum (II) complex of tacrine and its derivatives Application related reports

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • High-activity tacrine-platinum (II) complexes and synthesis method and application thereof
  • High-activity tacrine-platinum (II) complexes and synthesis method and application thereof
  • High-activity tacrine-platinum (II) complexes and synthesis method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] Accurately weigh 1.0 mmol of dichloro-bis(dimethylsulfoxide) platinum (II) and H-L in an amount of 1.0 mmol, dissolve H-L in 42 mL of methanol, and dichloro-bis(dimethylsulfoxide) Sulfone) platinum (II) was dissolved in 3 mL of dimethyl sulfoxide solution, the two solutions were mixed, reacted at 55 ° C for 12 hours, concentrated and evaporated to remove 55% of the solvent, cooled to room temperature and stood still, and a yellow solid was precipitated , suction filtration, and the solid was washed with water, methanol, and ether in sequence, and the solid was separated, and the target complex 1 was obtained after vacuum drying (yield 97.3%).

[0069] Identify the resulting yellow blocky crystals:

[0070] (1) Infrared spectrum, its spectrogram is as follows Figure 4 shown.

[0071] IR(KBr):3886,3783,3437,3397,2927,2382,1611,1552,1493,1443,1415,1118,1021,977,777,687,592,441cm -1 .

[0072] (2) Proton NMR spectrogram, its spectrogram is as Figure 5 shown.

[0073...

Embodiment 2

[0083] Weigh 1 mmol of complex 1 and 4,4'-dimethyl-2,2'-bipyridine, dissolve in 65 mL of ethanol, react at 55°C for 24 hours, concentrate and evaporate to remove 50% of the solvent, After cooling to room temperature and standing still, a reddish-brown solid precipitated out. The solid was separated, washed with water, methanol, and ether in sequence, and dried to obtain a reddish-brown solid product (yield 91.6%).

[0084] The resulting reddish-brown product is identified:

[0085] (1) Infrared spectrum, its spectrogram is as follows Figure 9 shown.

[0086] IR(KBr):3781,3694,3411,2928,2860,1614,1552,1493,1444,1414,1170,1122,924,520cm -1 .

[0087] (2) Proton NMR spectrogram, its spectrogram is as Figure 10 shown.

[0088] 1 H NMR (600MHz, DMSO-d 6 )δ9.26(d, J=5.2Hz, 1H), 9.19(d, J=6.0Hz, 2H), 9.11(d, J=4.9Hz, 1H), 8.39(s, 1H), 7.53(d, J=5.2Hz, 1H), 7.37(t, J=7.7Hz, 1H), 7.14–7.02(m, 2H), 2.79(s, 2H), 2.54(s, 2H), 2.52(s, 3H), 2.46(s,2H),2.43(s,6H).

[0089] (3) El...

Embodiment 3

[0095] Accurately weigh 1.0 mmol of complex 1 and 1.0 mmol of 4,7-diphenyl-1,10-phenanthroline, and dissolve them in 35 mL of 80v / v% methanol and acetonitrile (methanol and acetonitrile The volume ratio is 4:1) in the mixed solution, reacted at 80°C for 36 hours, concentrated and evaporated to remove 45% of the solvent, cooled to room temperature and stood still, filtered with suction, and the solid was washed with water, methanol and ether in sequence, and dried , the target product was obtained as a black solid (yield 86.3%).

[0096] Gained black product is identified:

[0097] (1) Infrared spectrum, its spectrogram is as follows Figure 12 shown.

[0098] IR(KBr):3957,3783,3696,3634,3429,2932,2379,1607,1557,1494,1420,1154,909,768,706,617,524cm -1 .

[0099] (2) Proton NMR spectrogram, its spectrogram is as Figure 13 shown.

[0100] 1 H NMR (500MHz, DMSO-d 6 )δ11.58(s,1H),9.72(s,1H),9.49(s,1H),9.37(s,1H),7.88(d,J=2.9Hz,2H),7.86(d,J=3.7 Hz,1H),7.71(s,6H),7.71(s,2H)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses high-activity tacrine-platinum (II) complexes and a synthesis method and application thereof, and relates to the technical field of medicine. The purpose of the invention is toprovide six high-activity tacrine-platinum (II) complexes having novel structures. The six high-activity tacrine-platinum (II) complexes have chemical structural formulas shown in the formulas 1 to 6. The high-activity tacrine-platinum (II) complexes can be used for preparation of antitumor drugs.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a highly active tacrine-platinum (II) complex and its synthesis method and application. Background technique [0002] In 1978, the FDA approved cisplatin as the first generation metal platinum antitumor drug for clinical use (Rosenberg, B.; et al. Nature, 1965, 205:698-699.), but its use was limited due to severe side effects. clinical application. With the development of economy and the change of lifestyle, the prevalence of cancer is getting higher and higher, seriously threatening human life and health. Although the currently synthesized platinum-based antineoplastic drugs have some anti-tumor activity, there are few drugs with better efficacy than cisplatin. Therefore, the design and development of platinum-based antineoplastic drugs need to be innovated on the basis of traditional ideas and breakthrough. [0003] In addition, tacrine is the first acetylcholinesterase inh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07F15/00A61P35/00
Inventor 覃其品谭明雄王书龙罗旭健
Owner YULIN NORMAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products